DOCSLIB.ORG

Metabotropic Glutamate Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metabotropic Glutamate Receptors Metabotropic Glutamate Receptors Molecular Pharmacology Francine C Acher Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR8601‑CNRS, Université René Descartes‑Paris V, 45 rue des Saints‑Pères, 75270 Paris Cedex 06, France. E‑mail: Francine.Acher@univ‑paris5.fr Francine C Acher is currently a CNRS Research Director within the Biomedical Institute of University Paris‑V (France). Her research focuses on structure/function studies and drug discovery using chemical tools (synthetic chemistry, molecular modeling), molecular biology and pharmacology within interdisciplinary collaborations. Introduction Glutamate is the major excitatory amino acid Figure 1 | Classification of the 8 Subtypes of transmitter in the brain. It is released from presynaptic mGlu Receptors vesicles and activates postsynaptic ligand‑gated Sequence similarity Group Transduction ion channel receptors (NMDA, AMPA and kainate receptors) to secure fast synaptic transmission.1 40 50 60 70 80 90% Glutamate also activates metabotropic glutamate | | | | | | (mGlu) receptors, which modulate its release, postsynaptic response, as well as the activity of mGlu1 2,3 other synapses. Glutamate has been shown to be I Gq +PLC involved in many neuropathologies such as anxiety, mGlu5 pain, ischemia, Parkinson’s disease, epilepsy and mGlu schizophrenia. Thus, because of their modulating 2 II Gi/Go ‑AC properties, mGlu receptors are recognized as mGlu3 promising therapeutic targets.4 It is expected that drugs acting at mGlu receptors will regulate the mGlu4 DRIVING RESEARCH FURTHER glutamatergic system without affecting the normal synaptic transmission. mGlu8 III Gi/Go ‑AC mGlu receptors are G‑protein‑coupled receptors mGlu7 (GPCRs). Eight subtypes have been identified mGlu and classified into three groups (I‑III) based upon 6 sequence homology, transduction mechanism and pharmacological profile (see Figure 1). Group I includes mGlu and mGlu receptors, which couple 1 5 the glutamate binding site is found (see Figure 3). to G and activate phospholipase C (PLC). Group II q This domain adopts a bilobate structure similar to (mGlu , mGlu ) and group III (mGlu , mGlu , mGlu 2 3 4 6 7 LIVBP (Leucine Isoleucine Valine Binding Protein), a and mGlu ) receptors couple to G/G and inhibit 8 i o bacterial periplasmic protein involved in the transport adenylyl cyclase (AC). Group I receptors are of hydrophobic amino acids;8‑10 these amino acids mostly located postsynaptically, thus their activation bind to an open conformation of the protein, which increases excitability. On the other hand, group II/ closes subsequently to trap them in between the two III receptors are generally presynaptic and their lobes. A similar binding mode has been proposed activation reduces glutamate release. Specific for glutamate and competitive agonists in the LIVBP ligands have been found for each group and some 5,6 domain (LIVBPD) of mGlu receptors. Moreover, it was of the subtypes, as described hereafter. shown that the closed conformation of this domain mGlu receptors belong to family 3 of the GPCR is required for receptor activation.11 Examination of superfamily.7 Similar to all GPCRs, mGlu receptors the glutamate binding site in the eight mGlu receptor 10 contain a heptahelical domain (HD) in the membrane subtype crystal structures (mGlu1) or homology region. In addition, like all members of family models12‑16 reveals a common binding motif for the 3, mGlu receptors are characterized by a large α‑amino and α‑carboxylic functions of glutamate,17 extracellular amino terminal domain (ATD) where while residues that bind the distal γ‑carboxylate vary Tocris Bioscience Scientific Review Series Tocris Bioscience Scientific Review Series Figure 2 | Competitive mGlu Receptor Ligand Structures R1 R2 CO2H R CO2H HO2C NH2 X H2O3P NH2 Ac‑Asp‑Glu R , R = H L‑Glutamic acid 1 2 X = CH R = H (S)‑AP4 R = H, R = CH CH(Ph) ADED 2 1 2 2 2 X = O R = H (S)‑SOP NAAG (LY 310225) X = CH2 R = Me MAP4 H N CO H H N CO H H2N CO2H H2N CO2H CO2H 2 2 2 2 H2N CO2H N CO H HO C CO2H R HO2C CO2H HO2C 2 2 CO2H (1S,3R)‑ACPD R = H (2R,4R)‑APDC ACPT‑I (+)‑ACPT‑III ACPT‑II R = CH2Ph BnAPDC R = CH2Naphthyl NM‑APDC R = CO2H APTC R1 R2 H CO2H HO C X 2 R1 HO C NH 2 CO2H 2 R3 R2 HO2C H H NH2 NH2 CO2H ABHxD‑I X = CH2 R1,R2,R3 = H LY 354740 R1, R2 = H L‑CCG‑I X = O R1,R2,R3 = H LY 379268 R1 = H, R2 = 3´‑CH3 3´Me‑CCG X = S R1,R2,R3 = H LY 389795 R1 = H, R2 = 3´‑CH2OH 3´HM‑CCG X = CH2 R1,R3 = H, R2 = F MGS0008 R1 = H, R2 = 3´‑CH2SH 3´SM‑CCG X = CH2 R1,R2 = H, R3 = F LY 354740‑6F HO C R1 = H, R2 = CO2H DCG IV 2 NH2 X = CO R1,R2 = H, R3 = F MGS0028 R1 = H, R2 = 9´xanthylethyl XE‑CCG‑I X = CH2 R2,R3 = H, R1 = OH HYDIA P(O)(OH)2 X = CH2 R1 = 3,4‑Cl2PhCH2O (1S,2R)‑APCPr R2 = H, R3 = F MGS0039 CO H R 2 NH2 HO2C H R = Me MCCG‑I R = 9´‑xanthylmethyl LY 341495 R = (3‑CIPh)2Et mCD‑CCG HO2C NH2 CO2H R NH 2 CO H OH R 2 O N O N N CO2H NH2 O NH O N O O N O 2 H H HO2C Me R = H Quis Z‑CBQA R = 9´thioxanthylmethyl (S)‑HomoAMPA R = benzyl BnQuis LY 393675 R2 R2 R1 CO2H R CO2H 1 CO H HO2C 2 NH X NH2 2 NH2 HO R1 R1 = H, R2 = OH (S)‑3,5‑DHPG R1,R2 = H (S)‑4CPG X = CO2H R1 = Me (S)‑MCPG R1 = Cl, R2 = H CHPG R1 = CO2H, R2 = H (S)‑3,4‑DCPG X = CO2H R1 = 9´‑thioxanthylmethyl R1 = H, R2 = Me 4C2MPG LY 367366 (LY 367385) X = PO3H2 R1 = H (S)‑PPG R1 = OH, R2 = Me 4C3H2MPG X = PO3H2 R1 = Me MPPG (LY 339840) X = PO3H2 R1 = cyclopropyl CPPG Agonists are shown in turquoise Antagonists are shown in dark blue (Bold Text Denotes Compounds Available From Tocris) | Metabotropic Glutamate Receptors from one subtype to another.14 Thus, not surprisingly, are already quite hydrophilic25 and few side effects are all competitive agonists are α‑amino acids, bearing predicted. Other glutamate analogs were also shown various selective functional groups on their side chain6 to be systemically active: (2R,4R)‑APDC, (S)‑DCPG, (see Figure 2). The first generation of orthosteric 3´Me‑CCG, 3´HM‑CCG and ACPT‑I (Figure 2). ligands was followed by a second generation of Desensitization was also feared with continuous allosteric modulators that bind in the HD.18 The first activation in the case of group II/III receptors, yet little molecule described as a non‑competitive mGlu was observed after several days of agonist activation. antagonist was CPCCOEt in the late nineties.19 Since Altogether these results promote a renewed interest then, numerous allosteric modulators have been in mGlu receptor competitive ligands. discovered by high‑throughput screening (HTS) in pharmaceutical companies.20‑22 Agonists (Table 1 and Figure ) The first agonist that was able to discriminate The purpose of the present article is to review our actual between ionotropic and metabotropic glutamate knowledge of the pharmacology of mGlu receptors. receptors was trans‑ACPD (1S,3R isomer).26 The Several detailed reviews2,3,5,6 have been published; ligand contributed considerably to the study of thus only the most potent and selective known ligands metabotropic glutamate receptors despite its lack of will be presented and emphasis will be placed on subtype selectivity.2,3,5 A limited number of molecules compounds that were recently disclosed. possess agonist activity across all mGlu receptors. Competitive Ligands The endogenous agonist L‑glutamate, L‑CCG‑I and ABHxD‑I are the most potent.2,3,5 It can be noted that An α‑amino acid moiety can be found in all L‑CCG‑I and ABHxD‑I are conformationally mGlu receptor competitive ligands (agonists and constrained and mimic the bioactive extended antagonists) and most of the side chains hold an glutamate conformation.23 Selectivity can be gained acidic function. In the ligand active conformations, by adding new chemical groups onto these the spatial disposition of these functional groups structures. is that of glutamate in an extended conformation, as predicted by pharmacophore23 and homology Group I models.14 For many years these compounds have Quisqualate (Quis) is the most potent group I agonist. However, it also activates AMPA receptors, thus its use is restricted. The most popular Figure 3 | Schematic Representation of an mGlu group I selective agonist is (S)‑3,5‑DHPG, yet it Receptor: the Two Orthosteric and Allosteric exhibits only moderate potency.2,3,5 CHPG27 and Binding Sites are Indicated Z/E‑CBQA28 have been claimed to specifically activate mGlu5 receptors, although the affinity of the former is quite low. To date, no specific mGlu Competitive ligands 1 competitive agonists have been disclosed. LIVBPD Group II extracellular LY 354740 was the first mGlu agonist reported to 24 ATD exhibit a nanomolar affinity. It is group II selective, as are its oxy (LY 379268) and thia (LY 389795) Allosteric derivatives.29 The introduction of a fluorine atom at modulators position 3 (MGS0008) or 6 (LY 354740‑6F) retained the potent activity, which was even enhanced when membrane a carbonyl group was added, as in the case of HD MGS0028.30 This series of bicyclic glutamate analogs was derived from the general agonist L‑CCG‑I, intracellular where increased potency and group II selectivity CTD was gained through the second hydrocarbon ring. However, it was recently shown that a methyl or hydroxymethyl substituent in the 3´ position (3´Me‑ CCG and 3´HM‑CCG) provided agonists with similar been considered as valuable research tools, but potency.31,32 Replacement of the hydroxyl functionality not as drug candidates, because of their poor LogP, at C3´ of 3´HM‑CCG, by a sulfydryl results in related to their highly polar chemical structures.
Load more

Recommended publications
  • Mglu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance Towards Their Primary Efficacy on Sleep Measures in Rats
    RESEARCH ARTICLE mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats Abdallah Ahnaou1*, Hilde Lavreysen1, Gary Tresadern2, Jose M. Cid2, Wilhelmus H. Drinkenburg1 1 Dept. of Neuroscience, Janssen Research & Development, A Division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340, Beerse, Belgium, 2 Neuroscience Medicinal Chemistry, Janssen Research & Development, Janssen-Cilag S.A., Jarama 75, Polígono Industrial, 45007, Toledo, Spain * [email protected] Abstract OPEN ACCESS G-protein-coupled receptor (GPCR) agonists are known to induce both cellular adaptations Citation: Ahnaou A, Lavreysen H, Tresadern G, Cid resulting in tolerance to therapeutic effects and withdrawal symptoms upon treatment dis- JM, Drinkenburg WH (2015) mGlu2 Receptor continuation. Glutamate neurotransmission is an integral part of sleep-wake mechanisms, Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary which processes have translational relevance for central activity and target engagement. Efficacy on Sleep Measures in Rats. PLoS ONE 10 Here, we investigated the efficacy and tolerance potential of the metabotropic glutamate (12): e0144017. doi:10.1371/journal.pone.0144017 receptors (mGluR2/3) agonist LY354740 versus mGluR2 positive allosteric modulator Editor: James Porter, University of North Dakota, (PAM) JNJ-42153605 on sleep-wake organisation in rats. In vitro, the selectivity and UNITED STATES potency of JNJ-42153605 were characterized. In vivo, effects on sleep measures were Received: July 12, 2015 investigated in rats after once daily oral repeated treatment for 7 days, withdrawal and con- Accepted: November 12, 2015 secutive re-administration of LY354740 (1–10 mg/kg) and JNJ-42153605 (3–30 mg/kg).
    [Show full text]
  • Selective Blockade of the Metabotropic Glutamate Receptor Mglur5 Protects Mouse Livers in in Vitro and Ex Vivo Models of Ischemia Reperfusion Injury
    International Journal of Molecular Sciences Article Selective Blockade of the Metabotropic Glutamate Receptor mGluR5 Protects Mouse Livers in In Vitro and Ex Vivo Models of Ischemia Reperfusion Injury Andrea Ferrigno 1,* ID , Clarissa Berardo 1, Laura Giuseppina Di Pasqua 1, Veronica Siciliano 1, Plinio Richelmi 1, Ferdinando Nicoletti 2,3 and Mariapia Vairetti 1 ID 1 Department of Internal Medicine and Therapeutics, Cellular and Molecular Pharmacology and Toxicology Unit, University of Pavia, 27100 Pavia, Italy; [email protected] (C.B.); [email protected] (L.G.D.P.); [email protected] (V.S.); [email protected] (P.R.); [email protected] (M.V.) 2 Department of Physiology and Pharmacology, Sapienza University, 00185 Roma, Italy; [email protected] 3 I.R.C.C.S. Neuromed, 86077 Pozzilli, Italy * Correspondence: [email protected]; Tel.: +39-0382-986451 Received: 20 November 2017; Accepted: 22 January 2018; Published: 23 January 2018 Abstract: 2-Methyl-6-(phenylethynyl)pyridine (MPEP), a negative allosteric modulator of the metabotropic glutamate receptor (mGluR) 5, protects hepatocytes from ischemic injury. In astrocytes and microglia, MPEP depletes ATP. These findings seem to be self-contradictory, since ATP depletion is a fundamental stressor in ischemia. This study attempted to reconstruct the mechanism of MPEP-mediated ATP depletion and the consequences of ATP depletion on protection against ischemic injury. We compared the effects of MPEP and other mGluR5 negative modulators on ATP concentration when measured in rat hepatocytes and acellular solutions. We also evaluated the effects of mGluR5 blockade on viability in rat hepatocytes exposed to hypoxia. Furthermore, we studied the effects of MPEP treatment on mouse livers subjected to cold ischemia and warm ischemia reperfusion.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • Advancing Quantitative Structure Activity Relationship Strategies in Ligand-Based Computer-Aided Drug Design
    ADVANCING QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP STRATEGIES IN LIGAND-BASED COMPUTER-AIDED DRUG DESIGN By Mariusz Butkiewicz Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY In Chemistry August, 2014 Nashville, Tennessee Approved: Jens Meiler, Ph.D. Brian O. Bachmann, Ph.D. David W. Wright, Ph.D. Clare M. McCabe, Ph.D. Copyright © 2014 by Mariusz Butkiewicz All Rights Reserved ii DEDICATION To my parents, my sister, and Nicole. iii ACKNOWLEDGEMENTS Over the past years, I have received support and encouragement from a great number of individuals to whom I am very grateful. I would like to express my deepest and sincere gratitude to my advisor, Dr. Jens Meiler. Coming to Nashville and joining the Meiler laboratory to start my graduate studies has been a tremendous opportunity and extraordinary experience in my life. Jens was an excellent mentor and supported me on each step in my graduate career. His guidance taught me how to approach scientific problems, how to ask-the right scientific questions, and how to write and present scientific work. Jens found the right balance between encouraging my own scientific explorations and providing invaluable guidance and help. I would like to thank Dr. Meiler for making the past several years such a pleasant academic experience. The members of my dissertation committee, Dr. David Wright, Dr. Brian Bachmann, and Dr. Clare McCabe, were a great source of support and guidance for my graduate work. Their insightful comments and constructive criticism gave appreciated impulses to my research.
    [Show full text]
  • The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review
    Journal of Clinical Medicine Review The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment— A Narrative Review Waldemar Kryszkowski 1 and Tomasz Boczek 2,* 1 General Psychiatric Ward, Babinski Memorial Hospital in Lodz, 91229 Lodz, Poland; [email protected] 2 Department of Molecular Neurochemistry, Medical University of Lodz, 92215 Lodz, Poland * Correspondence: [email protected] Abstract: Schizophrenia is a severe neuropsychiatric disease with an unknown etiology. The research into the neurobiology of this disease led to several models aimed at explaining the link between perturbations in brain function and the manifestation of psychotic symptoms. The glutamatergic hypothesis postulates that disrupted glutamate neurotransmission may mediate cognitive and psychosocial impairments by affecting the connections between the cortex and the thalamus. In this regard, the greatest attention has been given to ionotropic NMDA receptor hypofunction. However, converging data indicates metabotropic glutamate receptors as crucial for cognitive and psychomotor function. The distribution of these receptors in the brain regions related to schizophrenia and their regulatory role in glutamate release make them promising molecular targets for novel antipsychotics. This article reviews the progress in the research on the role of metabotropic glutamate receptors in schizophrenia etiopathology. Citation: Kryszkowski, W.; Boczek, T. The G Protein-Coupled Glutamate Keywords: schizophrenia; metabotropic glutamate receptors; positive allosteric modulators; negative Receptors as Novel Molecular Targets allosteric modulators; drug development; animal models of schizophrenia; clinical trials in Schizophrenia Treatment—A Narrative Review. J. Clin. Med. 2021, 10, 1475. https://doi.org/10.3390/ jcm10071475 1. Introduction Academic Editors: Andreas Reif, Schizophrenia is a common debilitating disease affecting about 0.3–1% of the human Blazej Misiak and Jerzy Samochowiec population worldwide [1].
    [Show full text]
  • Dynamic L-Glutamate Signaling in the Prefrontal Cortex and the Effects of Methylphenidate Treatment
    University of Kentucky UKnowledge Theses and Dissertations--Neuroscience Neuroscience 2012 DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT Catherine Elizabeth Mattinson University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Mattinson, Catherine Elizabeth, "DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND THE EFFECTS OF METHYLPHENIDATE TREATMENT" (2012). Theses and Dissertations--Neuroscience. 4. https://uknowledge.uky.edu/neurobio_etds/4 This Doctoral Dissertation is brought to you for free and open access by the Neuroscience at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Neuroscience by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine). I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.
    [Show full text]
  • Whittle-Neuropharm-2013.Pdf
    Neuropharmacology 64 (2013) 414e423 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model Nigel Whittle a,*, Claudia Schmuckermair a, Ozge Gunduz Cinar b,d, Markus Hauschild a, Francesco Ferraguti c, Andrew Holmes b,d, Nicolas Singewald a a Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80 e 82/III, A-6020 Innsbruck, Austria b Laboratory of Behavioral and Genomic Neuroscience, National Institute on Alcoholism and Alcohol Abuse, National Institutes of Health, Bethesda, MD 20852, USA Center for Neuroscience and Regenerative Medicine at the Uniformed Services University of the Health Sciences, Bethesda, MD c Department of Pharmacology, Innsbruck Medical University, A-6020 Innsbruck, Austria d Center for Neuroscience and Regenerative Medicine at the Uniformed Services University of the Health Sciences, Bethesda, MD, USA article info abstract Article history: Anxiety disorders are characterized by persistent, excessive fear. Therapeutic interventions that reverse Received 30 March 2012 deficits in fear extinction represent a tractable approach to treating these disorders. We previously re- Received in revised form ported that 129S1/SvImJ (S1) mice show no extinction learning following normal fear conditioning. We 31 May 2012 now demonstrate that weak fear conditioning does permit fear reduction during massed extinction Accepted 6 June 2012 training in S1 mice, but reveals specificdeficiency in extinction memory consolidation/retrieval. Rescue of this impaired extinction consolidation/retrieval was achieved with D-cycloserine (N-methly-D-aspar- Keywords: tate partial agonist) or MS-275 (histone deacetylase (HDAC) inhibitor), applied after extinction training.
    [Show full text]
  • Buyers' Guide
    Buyers’ Guide S119 Buyers’ Guide Suppliers’ Contact Details Amersham Biosciences UK Limited The Menarini Group Amersham Place www.menarini.com Little Chalfont Buckinghamshire HP7 9NA Moravek Biochemicals UK 577 Mercury Lane www5.amershambiosciences.com Brea Ca 92821 Avanti Polar Lipids Inc USA 700 Industrial Park Drive www.moravek.com Alabaster AL 35007 Roche Pharmaceuticals USA F. Hoffmann-La Roche Ltd www.avantilipids.com Pharmaceuticals Division Grenzacherstrasse 124 Bachem Bioscience Inc. CH-4070 Basel 3700 Horizon Drive Switzerland King of Prussia Telephone þ 41-61-688 1111 PA 19406 Unites States Telefax þ 41-61-691 9391 www.bachem.org www.roche.com Boehringer Ingelheim Ltd Ellesfield Avenue SIGMA Chemicals/Sigma-Aldrich Bracknell P.O. Box 14508 Berks RG12 8YS St. Louis, MO 63178-9916 UK USA www.boehringer-ingelheim.co.uk www.sigma-aldrich.com Calbiochem Tocris Cookson Ltd. EMD Biosciences, Inc. Northpoint, Fourth Way 10394 Pacific Center Court Avonmouth San Diego Bristol CA 92121 BS11 8TA USA UK www.emdbiosciences.com www.tocris.com S120 Buyers’ Guide Compound Supplier Buyers’ Guide a-methyl-5-HT a-Methyl-5-hydroxytryptamine Tocris ab-meATP ab-methylene-adenosine 5’-triphosphate Sigma-Aldrich bg-meATP bg-methylene-adenosine 5’-triphosphate Sigma-Aldrich (-)-(S)-BAYK8664 (-)-(S)-methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluromethylphenyl)-pyridine-5-carboxylate Sigma-Aldrich, Tocris (+)7-OH-DPAT (+)-7-hydroxy-2-aminopropylaminotetralin Sigma-Aldrich a-dendrotoxin Sigma-Aldrich (RS)PPG (R,S)-4-phosphonophenylglycine Tocris (S)-3,4-DCPG
    [Show full text]
  • Group II/III Metabotropic Glutamate Receptors Exert Endogenous Activity-Dependent Modulation of TRPV1 Receptors on Peripheral Nociceptors
    The Journal of Neuroscience, September 7, 2011 • 31(36):12727–12737 • 12727 Behavioral/Systems/Cognitive Group II/III Metabotropic Glutamate Receptors Exert Endogenous Activity-Dependent Modulation of TRPV1 Receptors on Peripheral Nociceptors Susan M. Carlton, Shengtai Zhou, Rosann Govea, and Junhui Du Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555-1069 There is pharmacological evidence that group II and III metabotropic glutamate receptors (mGluRs) function as activity-dependent autoreceptors, inhibiting transmission in supraspinal sites. These receptors are expressed by peripheral nociceptors. We investigated whether mGluRs function as activity-dependent autoreceptors inhibiting pain transmission to the rat CNS, particularly transient recep- tor potential vanilloid 1 (TRPV1)-induced activity. Blocking peripheral mGluR activity by intraplantar injection of antagonists LY341495 [(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid] (LY) (20, 100 ␮M, group II/III), APICA [(RS)-1- amino-5-phosphonoindan-1-carboxylic acid] (100 ␮M, group II), or UBP1112 (␣-methyl-3-methyl-4-phosphonophenylglycine) (30 ␮M, groupIII)increasedcapsaicin(CAP)-inducednociceptivebehaviorsandnociceptoractivity.Incontrast,groupIIagonistAPDC[(2R,4R)- 4-aminopyrrolidine-2,4-dicarboxylate] (0.1 ␮M) or group III agonist L-(ϩ)-2-amino-4-phosphonobutyric acid (L-AP-4) (10 ␮M) blocked the LY-induced increase. Ca 2ϩ imaging in dorsal root ganglion (DRG) cells confirmed LY enhanced CAP-induced Ca 2ϩ mobilization, which was blocked by APDC and L-AP-4. We hypothesized that excess glutamate (GLU) released by high intensity and/or prolonged stimulation endogenously activated group II/III, dampening nociceptor activation. In support of this, intraplantar GLU ϩ LY produced heat hyperalgesia, and exogenous GLU ϩ LY applied to nociceptors produced enhanced nociceptor activity and thermal sensitization.
    [Show full text]
  • Development of Allosteric Modulators of Gpcrs for Treatment of CNS Disorders Hilary Highfield Nickols A, P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Neurobiology of Disease 61 (2014) 55–71 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Review Development of allosteric modulators of GPCRs for treatment of CNS disorders Hilary Highfield Nickols a, P. Jeffrey Conn b,⁎ a Division of Neuropathology, Department of Pathology, Microbiology and Immunology, Vanderbilt University, USA b Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA article info abstract Article history: The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a promising new strategy Received 25 July 2013 with potential for developing novel treatments for a variety of central nervous system (CNS) disorders. Tradition- Revised 13 September 2013 al drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind en- Accepted 17 September 2013 dogenous ligands. Allosteric modulators target a site separate from the orthosteric site to modulate receptor Available online 27 September 2013 function. These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than Keywords: Allosteric modulator orthosteric ligands for the same receptors. Experimental evidence has revealed more nuanced pharmacological CNS modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with pos- Drug discovery itive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as “bitopic” ligands that GPCR interact with both the allosteric and orthosteric sites. Drugs targeting the allosteric site allow for increased drug Metabotropic glutamate receptor selectivity and potentially decreased adverse side effects.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • 1 Activation of the Same Mglur5 Receptors in the Amygdala Causes Divergent Effects 2 on Specific Versus Indiscriminate Fear 3
    1 Activation of the same mGluR5 receptors in the amygdala causes divergent effects 2 on specific versus indiscriminate fear 3 4 Mohammed Mostafizur Rahman1,2,#, Sonal Kedia1,#, Giselle Fernandes1#, Sumantra 5 Chattarji1,2,3* 6 7 1National Centre for Biological Sciences, Tata Institute of Fundamental Research, 8 Bangalore 560065, India 9 10 2Centre for Brain Development and Repair, Institute for Stem Cell Biology and 11 Regenerative Medicine, Bangalore 560065, India 12 13 3Centre for Integrative Physiology, Deanery of Biomedical Sciences, University of 14 Edinburgh, Hugh Robson Building, George Square, Edinburgh EH89XD, UK 15 16 17 * Corresponding Author: Prof. Sumantra Chattarji 18 Centre for Brain Development and Repair, Institute for 19 Stem Cell Biology and Regenerative Medicine and 20 National Centre for Biological Sciences 21 Bangalore 560065, INDIA 22 E-Mail: [email protected] 23 # Equal contribution 24 1 25 Abstract 26 27 Although mGluR5-antagonists prevent fear and anxiety, little is known about how the 28 same receptor in the amygdala gives rise to both. Combining in vitro and in vivo 29 activation of mGluR5 in rats, we identify specific changes in intrinsic excitability and 30 synaptic plasticity in basolateral amygdala neurons that give rise to temporally distinct 31 and mutually exclusive effects on fear-related behaviors. The immediate impact of 32 mGluR5 activation is to produce anxiety manifested as indiscriminate fear of both tone 33 and context. Surprisingly, this state does not interfere with the proper encoding of tone- 34 shock associations that eventually lead to enhanced cue-specific fear. These results 35 provide a new framework for dissecting the functional impact of amygdalar mGluR- 36 plasticity on fear versus anxiety in health and disease.
    [Show full text]